Versão HTML básica
355
Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Rev Bras Hematol Hemoter. 2012;34(5):352-5
13. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage:
mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195-214.
14. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in
myeloid leukemias? Blood. 2011;117(22):5816-26.
15. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Muller MC, Lahaye T,
et al. Molecular and chromosomal mechanisms of resistance to imatinib
(STI571) therapy. Leukemia. 2002;16(11):2190-6.
16. Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA
mutation in chronic myelogenous leukemia. Leukemia. 2010;24(6):1105-12.
17. The International Agency for Research on Cancer. Classification of
tumours of haematopoietic and lymphoid tissues. 4
nd
ed. Lyon: WHO
Press; 2008. 439 p. ( IARC WHO Classification of Tumours).
18. Draper HH, Hadley M. Malondialdehyde determination as index of lipid
peroxidation. Methods Enzymol. 1990;186:421-31.
19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS,
Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological
fluids. Anal Biochem. 1982;126(1):131-8.
20. Faderl S, Talpaz M, Estrov Z, O´Brien S, Kurzrock R, Kantarjian, H. The
biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-72.
21. Bortolheiro TC, Chiattone CS. Leucemia mielóide crônica: história
natural e classificação. Rev Bras Hematol. Hemoter. 2008;30(1):3-7.
22. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia
(CML). Best Pract Res Clin Haematol. 2009;22(3):295-302.
23. Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet.
Chronic myeloid leukemia. Lancet. 2007;370(9584):342-50. Comment
in: Lancet. 2007;370(9593):1127.
24. Deshmukh C, Saikia T, Baksi A, Amare-Kadam P, Baisane C, Parikh P.
Imatinib mesylate in chronic myeloid leukemia: a prospective single arm.
Non-randomized study. J Assoc Physicians India. 2005;53:291-5.
25. Syed NN, Usman M, Khaliq G, Adil SN, Khurshid M. Clinico-pathologic
features of chronic myeloid leukemia and risk stratification according to
Sokal score. J. Coll Physicians Surg Pak. 2006;16(5):336-9.
26. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al.
Prognostic discrimination in “good-risk” chronic granulocytic leukemia.
Blood. 1984;63(4):789-99.
27. Campos MG, ArantesAM, Oliveira JSR, Chauffaille ML. Chronic myeloid
leukemia: a disease of youth in Brazil. Leuk Res. 2010;34(4):542-4.
28. Cerutti PA. Pro-oxidant status and tumor promotion. Science.
1985;227(4685):375-81.
29. Ahmad R, Anil KT, Payal T, Ranjana S, Sushma S, Raj KS. Oxidative
stress and antioxidant status in patients with chronic myeloid leukemia.
Ind J Clin Biochem. 2008; 23(4):328-33.
30. Ahmad R, Tripathi AK, Tripathi P, Singh S, Singh R, Singh RK.
Malondialdehyde and protein carbonyl as biomarkers for oxidative stress
and disease progression in patients with chronic myeloid leukemia. In
Vivo [Internet]. 2008 [cited 2010 Jun 21];22(4):525-8. Available from:
http://iv.iiarjournals.org/content/22/4/525.long
31. Ciarcia R, D’angelo D, Pacilio C, Pagnini D, Galdiero M, Fiorito F, et
al. Dysregulated calcium homeostasis and oxidative stress in chronic
myeloid leukemia (CML) cells. J Cell Physiol. 2010;224(2):443-53.
32. Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP. Free
radicals antioxidant enzymes and lipid peroxidation in different types of
leukemias. Clin Chim Acta. 2000;293(1-2):53-62.
33. Oltra AM, Carbonell F, Tormos C, Iradi A, Guillermo T, Saez GT.
Antioxidant enzyme activities and the production of MDA and 8-oxo-dg in
chronic lymphocytic leukemia. Free Radic Biol Med. 2001;30(11):1286-92.
34. Battisti V, Madersa LD, Bagatinia MD, Santos KF, Spanevello RM,
Maldonado PA, et al. Measurement of oxidative stress and antioxidant
status in acute lymphoblastic leukemia patients. Clin Biochem.
2008;41(7-8):511-8.
35. ZhouY, Hileman EO, PlunkettW, KeatingMJ, Huang P. Free radical stress
in chronic lymphocytic leukemia cells and its role in cellular sensitivity
to ROS-generating anticancer agents. Blood [Internet]. 2003[cited 2011
Jan 23];101(10):4098-104. http://bloodjournal.hematologylibrary.org/
cgi/pmidlookup?view=long&pmid=12531810
36. Goldman JM. Treatment strategies for CML. Best Pract Res Clin
Haematol. 2009; 22(3):303-13.
37. Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S; Consorzio
Interuniversitario Nazionale per Bio-Oncologia (CINBO). Tyrosine
kinase inhibitors. Curr Cancer Drug Targets. 2010;10(5):462-83.
38. La Rosée P, Deininger MW Resistance to imatinib: mutations and
beyond. Semin Hematol. 2010;47(4):335-43.
39. Delamain MT, Conchon M. Os inibidores de tirosino quinase de segunda
geração. Rev Bras Hematol Hemoter. 2008;30(suppl.1):37-40 .
40. Slupphaug G, Kavli B, Krokan HE. The interacting pathways for
prevention and repair of oxidative DNA damage. Mutat Res. 2003;531(1-
2):231-51.
41. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I,
Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-
mutagenesis via reactive oxygen species to encode imatinib resistance.
Blood [Internet]. 2006 [cited 2011 Jan 21];108(1):319-27. Available
from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895841
xxx